This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEDAF0IH_M.jpg
The Cantlay/Harper trial, which was originally scheduled for November 13, will now be dismissed. This follows a similar outcome in June when GSK settled with claimant James Goetz. This strategy comes as GSK faces numerous lawsuits concerning the alleged cancer-causing properties of Zantac.
GSK, with an adjusted market cap of $76.25B according to InvestingPro data, has not admitted liability despite these settlements. The company continues to assert its commitment to “vigorously defend” against all remaining Zantac lawsuits. This stance is “based on the facts and the science,” according to the company.
The U.S. Food and Drug Administration’s (FDA) decision to pull Zantac off shelves in 2020 led to thousands of lawsuits against GSK. A judge had previously denied GSK’s attempt to prevent expert testimony associating Zantac with cancer.
GSK, which has maintained dividend payments for 23 consecutive years according to InvestingPro Tips, faced a hefty £45m legal bill in the previous year. Yet, it continues to deny liability in these confidential settlements. The company’s approach was communicated to investors as GSK shares rose 1.1% to 1,538.60 pence in London trading on Wednesday. The company’s shares have been trading near their 52-week high, with a return of 10.55% over the last three months.
For more detailed insights and tips about GSK and other companies, consider subscribing to InvestingPro’s premium service. This service includes additional tips and real-time metrics, helping investors make more informed decisions. To learn more, visit InvestingPro Pricing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
